Beta-O2 Technologies Overview
Beta-O2 Technologies is a biomedical company developing a proprietary implantable bioreactor, the Air, for the treatment of patients with type 1 diabetes. The Air is a small medical device that is implanted in a minimally invasive procedure. The device, which contains islets of Langerhans, is intended to free patients from insulin injections and continuous monitoring of glucose levels. The device also reduces the risk of hypoglycemic episodes and other complications of the condition. Because the Air device contains living cells, the patient needs to refill the air in the device using a replenishing device, which includes a dedicated injector.
Cumulative Funding Raised Over Time ($)
$5.0MFeb 2007
$5.0MJan 2018
$7.0MMar 2004
$7.0MMar 2015
$7.2MSep 2017
Latest News
Beta-O2 Technologies to begin human trials on new artificial pancreas
growth-positive
https://www.jpost.com/Israel-News/Hillels-Tech-Corner-Using-tech-to-replicate-the-pancreas-601531
Beta-O2 Technologies has developed a device called ßAir® that replaces the pancreas and monitors and controls glucose levels in the human body. The device offers a safe environment for transplanted cells without the need for immune-suppressive drugs. The company has completed two human trials and plans to conduct a second trial in 2020. Beta-O2 has raised $40 million in funding from various investors. If successful, the device could greatly improve the management of type-1 diabetes.
Investment
growth-positive
Positive breakthrough made in implanted islet cells technology - Diabetes
A breakthrough in implanted islet cell technology by MIT and Beta-O2 Technologies could lead to successful treatment for people with type 1 diabetes. The technology provides living pancreatic islet cells with their own supply of oxygen through an implantable device. Tests on rats showed that 90% of the islets survived for several months and blood sugar levels remained normal. Further development is underway to create a more sophisticated version of the device. The findings have been published in the journal Scientific Reports.
Customers
growth-positive
Japanese Technology Holding Company IRI Wants to Raise $30 Million in Tel Aviv IPO
Internet Research Institute Inc., a Tokyo-headquartered tech holding company, plans to raise $20-$30 million through an IPO on the Tel Aviv Stock Exchange. The company, which registered in Israel in August, aims to bring Israeli technologies and ideas to the Japanese market in the domains of IoT, cybersecurity, and AI. The IPO underwriter is Discount Capital Underwriting Ltd., and the funds raised will be used for local research and development or acquisitions and investments. Internet Research Institute has annual revenues of $8 million and net profits of around $2 million. In September, the company invested $200 thousand in Beta-O2 Technologies Ltd., a biotech company. The IPO is expected to have a positive impact on the companys growth.
Public TradingInvestment
growth-positive
FDA decision boosts Beta-02's artificial pancreas
Beta-O2 Technologies, an Israeli diabetes company, has developed a device that contains living pancreas cells that automatically secrete insulin into the bloodstream. The US Food and Drug Administration (FDA) has recently implemented a regulation requiring companies that implant insulin-secreting stem cells to use such a device. This regulation has sparked interest in Beta-O2 Technologies, as they have been working on a similar product for over a decade. The company is currently examining partnerships with various stem cell companies, including Kadimastem Ltd. The device has undergone successful trials with live cells, but not yet with stem cells.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $8.22M |
| Last funding | $25K |
| Stage | Mature |
| Rounds | 6 |
| Investors | 5 |
Team Members
2
Employees: 11-50
Web & Social Links
| Website | beta-o2.com |
Locations
Amal Street 11, Rosh Haayin, Israel
Photos & Videos
2 item(s)
Beta-O2 Technologies Business
Business models
B2B
Product stage
Released
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue EngineeringMedical DevicesMedical Treatment & TherapeuticsTarget Customer
Healthcare & Life SciencesHealthcarePatientsProvidersCore Technology
BiologicalsCellsTags (4)
biotechnologyminimally-invasivediabetesmedical-devicesGeographic Markets
GlobalBeta-O2 Technologies Financials
$8.22M
Total funding
Undisclosed
Capital raised
$25K
Last funding
Mature
Funding stage
6
Total rounds
5
Investors
Cumulative Funding Raised Over Time ($)
$5.0MFeb 2007
$5.0MJan 2018
$7.0MMar 2004
$7.0MMar 2015
$7.2MSep 2017
Private Equity Funding
Undisclosed Round
Jan 2018
$25K
Sherpa InnoVentures
Undisclosed Round
Sep 2017
$200K
Internet Research Institute (IRI)
Undisclosed Round
Mar 2015
Undisclosed
Sherpa InnoVentures
Undisclosed Round
Feb 2007
$5M
Aurum Ventures M.K.I
Seed
Mar 2004
$2M
SCP Vitalife, Heznek Fund
Non-Equity Funding
GrantEvent
Sep 2014
$1M
JDRF
Beta-O2 Technologies Lifecycle
Cumulative Funding Raised Over Time
$5.0MFeb 2007
$5.0MJan 2018
$7.0MMar 2004
$7.0MMar 2015
$7.2MSep 2017
All Events
Undisclosed Round
Jan 2018
$25K
Sherpa InnoVentures
Undisclosed Round
Sep 2017
$200K
Internet Research Institute (IRI)
Undisclosed Round
Mar 2015
Undisclosed
Sherpa InnoVentures
Undisclosed Round
Feb 2007
$5M
Aurum Ventures M.K.I
Seed
Mar 2004
$2M
SCP Vitalife, Heznek Fund
GrantEvent
Sep 2014
$1M
JDRF
Beta-O2 Technologies News
9 articlesBeta-O2 Technologies to begin human trials on new artificial pancreas
growth-positive
https://www.jpost.com/Israel-News/Hillels-Tech-Corner-Using-tech-to-replicate-the-pancreas-601531
Beta-O2 Technologies has developed a device called ßAir® that replaces the pancreas and monitors and controls glucose levels in the human body. The device offers a safe environment for transplanted cells without the need for immune-suppressive drugs. The company has completed two human trials and plans to conduct a second trial in 2020. Beta-O2 has raised $40 million in funding from various investors. If successful, the device could greatly improve the management of type-1 diabetes.
Investment
growth-positive
Positive breakthrough made in implanted islet cells technology - Diabetes
A breakthrough in implanted islet cell technology by MIT and Beta-O2 Technologies could lead to successful treatment for people with type 1 diabetes. The technology provides living pancreatic islet cells with their own supply of oxygen through an implantable device. Tests on rats showed that 90% of the islets survived for several months and blood sugar levels remained normal. Further development is underway to create a more sophisticated version of the device. The findings have been published in the journal Scientific Reports.
Customers
growth-positive
Japanese Technology Holding Company IRI Wants to Raise $30 Million in Tel Aviv IPO
Internet Research Institute Inc., a Tokyo-headquartered tech holding company, plans to raise $20-$30 million through an IPO on the Tel Aviv Stock Exchange. The company, which registered in Israel in August, aims to bring Israeli technologies and ideas to the Japanese market in the domains of IoT, cybersecurity, and AI. The IPO underwriter is Discount Capital Underwriting Ltd., and the funds raised will be used for local research and development or acquisitions and investments. Internet Research Institute has annual revenues of $8 million and net profits of around $2 million. In September, the company invested $200 thousand in Beta-O2 Technologies Ltd., a biotech company. The IPO is expected to have a positive impact on the companys growth.
Public TradingInvestment
growth-positive
FDA decision boosts Beta-02's artificial pancreas
Beta-O2 Technologies, an Israeli diabetes company, has developed a device that contains living pancreas cells that automatically secrete insulin into the bloodstream. The US Food and Drug Administration (FDA) has recently implemented a regulation requiring companies that implant insulin-secreting stem cells to use such a device. This regulation has sparked interest in Beta-O2 Technologies, as they have been working on a similar product for over a decade. The company is currently examining partnerships with various stem cell companies, including Kadimastem Ltd. The device has undergone successful trials with live cells, but not yet with stem cells.
Partners
growth-positive
Beta-O2 Technologies Receives Investment from Sherpa Innoventures - FinSMEs
Beta-O2 Technologies, a biomedical company based in Israel, has received an investment from Sherpa Innoventures. The funding will be used to accelerate the companys clinical development of the ßAir bio-artificial Pancreas for type 1 diabetes and other pipeline products. The company is led by CEO Dr. Yuval Avni and is also backed by Aurum Ventures, SCP Vitalife Partners, Pitango Venture Capital, and Saints Capital.
Investment
growth-positive
Beta-O2 testing cure for type 1 diabetes
Israels Beta-O2 has implanted its ßAir bio-artificial pancreas in the first of eight diabetes patients in Sweden as part of a pilot human study. The implantable system aims to provide a potential cure for type 1 diabetes by protecting transplanted islet cells from the immune reaction to foreign matter and ensuring a consistent supply of oxygen. The company plans to use human stem cells and animal-derived cells in future experiments. If successful, the device could simulate the functionality of a functioning pancreas in response to varying glucose levels. Beta-O2 is backed by lead investor Aurum Ventures.
Customers
growth-positive
Beta-O2 starts clinical trial for artificial pancreas
Beta-O2 Technologies has successfully implanted the first patient participating in the companys study of the ßAir Bio-Artificial Pancreas, a potential treatment and cure for type 1 diabetes. The study, funded by a grant from JDRF, aims to evaluate the safety and efficacy of the ßAir macro-encapsulation with human islets of Langerhans. If successful, the company estimates that an efficacy trial among 50 patients will be necessary before marketing the product. Beta-O2 Technologies has raised $23 million since its founding and estimates the entire process will cost $15-20 million. The companys investors include SCP Vitalife, Aurum Ventures, Pitango Venture Capital, and Saints.
Investment
growth-positive
Future Tech: Beta-O2 Announces Implantable Device to Automatically Manage Blood Sugars
The JDRF has announced a $500,000 grant to Beta-O2 Technologies Ltd. for their ßAir bio-artificial pancreas, which aims to eliminate the need for insulin injections and carbohydrate counting for type 1 diabetes patients. The grant will fund a pilot human study of the device. Beta-O2 has developed a special delivery system that protects the implanted cells from the bodys immune system and uses daily injections of oxygen to feed the cells. The technology has shown success in animal models and one human patient trial. Beta-O2 hopes to have patient trials running in Europe by 2016 and expects approval in Europe by 2019 or 2020. The technology is expected to be available to the public in the US several years after that.
InvestmentCustomers
Employee Info
| Employees (range) | 11-50 |
| Exact count | 15 |
| Team members | 2 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Beta-O2 Technologies Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| Missing | markets |
| BI Verification | Sharon Shapira |
| Registrar ID | 512870221 |
| Crunchbase | beta-o2-technologies |
| Phone | +97239180700|+972525490408 |
| Creator | Tamar Weiss |
| Creator email | tamar.e.weiss@gmail.com |
| Last updater | Matan Eblagon |
| Updater email | matane@sncentral.org |
| Last update | 2023-09-18T00:00:00.000Z |
| Created | 2014-08-11T00:00:00.000Z |